Everything you need to know about TMS During Pregnancy and Breastfeeding: Safety, Benefits, and Current Research — how it works, what it costs, and how to find a provider who actually knows what they're doing.

Perinatal depression, which includes depression during pregnancy and the postpartum period, affects approximately 10-20% of mothers and represents one of the most common complications of childbirth. Left untreated, perinatal depression is associated with adverse outcomes for both mother and child, including poor prenatal care, preterm birth, developmental delays, and mother-infant attachment problems.

Standard antidepressant medications pose challenges during pregnancy due to potential fetal exposure and uncertain risk-benefit ratios. Electroconvulsive therapy (ECT), while effective, requires anesthesia and carries risks. Transcranial magnetic stimulation offers a non-pharmacological alternative that may be safer for pregnant women and their developing babies. However, the evidence base, while growing, remains limited.

What You’ll Learn

• Why TMS is an attractive option for perinatal depression with minimal systemic effects
• Research findings showing 40-70% response rates in pregnant patients with no adverse fetal outcomes
• Theoretical concerns about TMS during pregnancy and why they have not been substantiated
• Why TMS is compatible with breastfeeding unlike many psychiatric medications
• Practical considerations for scheduling and positioning during pregnancy

Understanding Perinatal Depression

Perinatal depression is distinct from depression occurring at other times of life. The hormonal fluctuations, metabolic changes, sleep disruption, and psychosocial stressors of pregnancy and new motherhood create a unique vulnerability.

During pregnancy, depression may manifest as:

• Persistent sadness or irritability
• Difficulty bonding with the developing baby
• Changes in appetite and sleep beyond typical pregnancy symptoms
• Anxiety about pregnancy, delivery, or parenthood
• Withdrawal from prenatal care

Postpartum depression symptoms are similar but may also include:

• Difficulty caring for or bonding with the baby
• Overwhelming fatigue
• Feelings of worthlessness or inadequacy as a mother
• Intrusive thoughts about harming the baby (requires urgent evaluation)

Why TMS Is Attractive During Pregnancy

The appeal of TMS for perinatal depression stems from several key features:

Minimal systemic effects — Unlike medications that circulate through the bloodstream and cross the placenta, TMS produces localized effects in the brain. The magnetic field does not reach the fetus directly.

Non-invasive — No surgery, anesthesia, or medication administration required.

Established safety profile — TMS has been used in thousands of patients with a well-characterized safety profile, though data in pregnancy specifically is limited.

Targeted mechanism — TMS can directly modulate the neural circuits involved in mood regulation, potentially bypassing systemic pathways.

Possibility of breastfeeding — Unlike many medications that are contraindicated during breastfeeding, TMS does not introduce any substances into breast milk.

What the Evidence Shows

TMS During Pregnancy

The evidence for TMS during pregnancy is limited but growing. Several case series and small trials have reported:

A 2019 systematic review identified 8 studies of TMS for depression during pregnancy involving approximately 80 patients. Across studies, TMS was well-tolerated with no adverse fetal outcomes reported. Depression response rates ranged from 40-70%, comparable to general TMS populations.

A prospective study at Massachusetts General Hospital treated 16 pregnant women with treatment-resistant depression using standard TMS protocols. The treatment was well-tolerated, and 60% of participants showed significant improvement in depression scores. No adverse obstetric or fetal outcomes occurred, and all pregnancies resulted in full-term, healthy deliveries.

One of the largest studies to date, conducted in Brazil, treated 50 pregnant women with moderate-to-severe depression using TMS. The active treatment group showed significantly greater improvement than controls, with no differences in gestational age, birth weight, or neonatal outcomes.

While these results are encouraging, the sample sizes remain small, and larger controlled trials are needed to establish definitive safety and efficacy.

TMS and Fetal Safety

The theoretical concerns about TMS during pregnancy center on:

Heat generation — The magnetic pulses can produce local heating in the skull (typically less than 1 degree Celsius). This is unlikely to affect the fetus, which is separated from the stimulation site by the skull and brain tissue.

Fetal magnetic field exposure — The TMS magnetic field dissipates rapidly with distance and does not penetrate to the fetus. Measured fetal magnetic field exposure is negligible.

Acoustic effects — The clicking sound of the TMS coil produces some acoustic exposure, but this is easily mitigated with earplugs.

Uterine contractions — There is no evidence that TMS stimulates uterine contractions. The magnetic field does not activate uterine tissue.

Maternal stress reduction — Untreated maternal depression is associated with adverse fetal outcomes including preterm birth and low birth weight. TMS may benefit fetal development by reducing maternal stress.

TMS While Breastfeeding

Unlike most psychiatric medications, TMS does not introduce any substances into breast milk. This makes it an attractive option for breastfeeding mothers who need treatment for depression but wish to continue nursing.

The practical considerations are minimal:

• No waiting period required between TMS and breastfeeding
• No effect on milk supply or composition
• No risk of infant medication exposure
• Can be scheduled around infant feeding routines

A 2022 survey of mothers who received TMS while breastfeeding found high satisfaction with the ability to continue nursing without interruption. No infant adverse events related to breastfeeding were reported.

Treatment Considerations for Pregnant and Postpartum Women

Timing

TMS during pregnancy is typically initiated when:

• Depression is moderate to severe
• Psychotherapy has not been effective or is not appropriate
• Patient prefers non-pharmacological treatment
• Risk-benefit analysis favors TMS over medications

The first trimester is when fetal organ development occurs, and some clinicians may prefer to delay elective treatments. However, severe untreated depression also poses risks during this critical period. Decisions should be individualized.

Session Logistics

Pregnant women may find TMS sessions increasingly challenging as pregnancy progresses due to:

• Physical discomfort lying flat (support pillows can help)
• Frequent bathroom breaks
• Nausea or fatigue

Scheduling flexibility and accommodations for pregnancy-related needs are important.

Co-occurring Anxiety

Perinatal depression is frequently accompanied by anxiety. TMS protocols can address both depression and anxiety, as the DLPFC plays a role in both conditions. Some evidence suggests that anxiety symptoms may be more resistant to TMS than depression, requiring higher treatment doses or longer protocols.

Integration with Perinatal Care

Optimal care for perinatal depression should include:

• Close coordination between TMS providers and obstetricians
• Monitoring of pregnancy progress throughout treatment
• Attention to psychosocial support and home environment
• Planning for postpartum care and relapse prevention
• Support for infant feeding decisions (breastfeeding or formula)

The Bottom Line

TMS represents a promising option for perinatal depression that offers antidepressant efficacy without fetal medication exposure or risks during breastfeeding. The current evidence, while limited, shows no evidence of harm and suggests comparable efficacy to TMS in non-pregnant populations.

Pregnant and breastfeeding women with depression should discuss TMS with their obstetrician and psychiatrist to determine whether it is an appropriate option for their specific situation.

If you are pregnant or postpartum and experiencing depression, talk to your healthcare provider. Resources are available through Postpartum Support International (postpartum.net) and the Marce Society for reproductive mental health.